KemPharm, Inc. (NASDAQ:KMPH – Get Rating) CEO Travis C. Mickle acquired 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 25th. The stock was purchased at an average price of $4.37 per share, for a total transaction of $13,110.00. Following the acquisition, the chief executive officer now directly owns 39,521 […]
(PLX AI) - Orphazyme plans to present the proposal to Danish High Court and all known creditors and will be voted on at a meeting on 30 May. • Orphazyme: if restructuring proposal is adopted by the creditors
Equities analysts predict that KemPharm, Inc. (NASDAQ:KMPH – Get Rating) will report $3.07 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for KemPharm’s earnings. The highest sales estimate is $4.13 million and the lowest is $2.00 million. KemPharm reported sales of $12.12 million during the same […]
Analysts expect KemPharm, Inc. (NASDAQ:KMPH – Get Rating) to report ($0.06) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for KemPharm’s earnings, with estimates ranging from ($0.08) to ($0.03). KemPharm reported earnings per share of ($1.61) during the same quarter last year, which suggests a […]